Welcome Guest Yousubmit logged 0 times

USFDA rejects SPARC#39;s epilepsy drug application

The company has received a Complete Response Letter (CRL) from the USFDA for its new drug application for Elepsia XR, Levetiracetam extended-release tablets in strengths of 1,000 mg and 1,500 mg, SPARC said in a regulatory filing....
Surveys4Checks.com Get Paid to Take Surveys